Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells

Journal of the National Cancer Institute

Volumn 88, Issue 19, 1996, Pages 1383-1392

  Stein, Ulrike ^a   Walther, Wolfgang ^a   Shoemaker, Robert H ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DOXORUBICIN; INTERLEUKIN 2; TUMOR NECROSIS FACTOR; VINCRISTINE;

ARTICLE; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE;

EID: 0029758014     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.19.1383     Document Type: Article

References (42)

1. Germann UA, Pastan I, Gottesman MM. P-glycoproteins: mediators of multidrug resistance. Semin Cell Biol 1993;4:63-76.
2. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-71.
3. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 1993;60:157-80.
4. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993;72:3553-63.
5. Evans CH, Baker PD. Decreased P-glycoprotein expression in multidrugsensitive and -resistant human myeloma cells induced by the cytokine leukoregulin. Cancer Res 1992;52:5893-9.
6. Walther W, Stein U. Influence of cytokines on mdrl expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 1994;120:471-8.
7. Rosenblum MG, Donato NJ, Gutterman JU. Characterization of human tumor necrosis factor-alpha antiproliferative effects in human cells in culture, Lymphokine Res 1988;7:107-17.
8. Frei E 3d, Spriggs D. Tumor necrosis factor: still a promising agent. J Clin Oncol 1989;7:291-4.
9. Stein RC, Malkovska V, Morgan S, Galazka A, Aniszewski C, Roy SE, et al. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [published erratum appears in Br J Cancer 1991;63:1029]. Br J Cancer 1991;63:275-8.
10. Stein RC, Dalgleish AG. Immunomodulatory agents: the cytokines. Eur J Cancer 1994;30A:400-4.
11. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine genemodified tumor cells. Hum Gene Ther 1994;5:153-64.
12. Gilboa E, Lyerly HK, Vieweg J, Saito S. Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol 1994;5:409-17.
13. Uckert W, Walther W. Retrovirus-mediated gene transfer in cancer therapy. Pharmacol Ther 1994;63:323-47.
14. Walther W, Stein U, Pfeil D. Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity. Int J Cancer 1995;61:832-9.
15. Mitchell MS. Combining chemotherapy with biological response modifiers in treatment of cancer. J Natl Cancer Inst 1988;80:1445-50.
16. Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, et al. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 1992; 52:3029-34.
17. Iwahshi T, Okochi E, Ono K, Sugawara I, Tsuruo T, Mori S. Establishment of multidrug resistant human colorectal carcinoma HCT-15 cell lines and their properties. Anticancer Res 1991;11:1309-12.
18. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 1981;41:1751-6.
19. Chu G, Hayakawa H, Berg P. Electroporation for the efficient transfection of mammalian cells with DNA. Nucleic Acids Res 1987;15:1311-26.
20. Walther W, Stein U, Eder C. RNA analysis using miniprep RNA in reverse transcription PCR. Biotechniques 1994;17:674-5.
21. Brenner CA, Daniel SL, Adler RR. Cytokine mapping: observation and quantification of cytokine mRNA in small numbers of cells using the polymerase chain reaction. In: Balkwill FR, editor. Cytokines - a practical approach. Oxford (UK): Oxford Univ Press, 1989:51-9.
22. Noonan KF, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:7160-4.
23. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-33.
24. Bonavida B, Tsuchitani T, Zighelboim J, Berek JS. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells, Gynecol Oncol 1990;38:333-9.
25. Schiller JH, Bittner G. Anti-proliferative effects of tumor necrosis factor, gamma interferon and 5-fluorouracil on human colorectal carcinoma cell lines. Int J Cancer 1990;46:61-6.
26. Vigani A, Chiara S, Miglietta L, Repetto L, Conte PF, Cimoli G, et al. Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity. Gynecol Oncol 1991;41:52-5.
27. Valenti M, Cimoli G, Parodi S, Mariani GL, Venturini M, Conte PF, et al. Potentiation of tumor necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications. Eur J Cancer 1993;29A:1157-61.
28. Oppenheim MH, Lotze MT. Interleukin-2: solid-tumor therapy. Oncology 1994;51:154-69.
29. Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Kawabata K, et al. In vivo effects of human recombinant tumor necrosis factor alone and in combination with other biological response modifiers on human digestive organ cancer xenografts transplanted in nude mice. Biotherapy 1991;3: 337-44.
30. Ijzermans JN, Scheringa M, van der Schelling GP, Geerling RA, Marquet RL, Jeekel J. Injection of recombinant tumor necrosis factor directly into liver metastases: an experimental and clinical approach. Clin Exp Metastasis 1992;10:91-7.
31. Sone S, Ogura T. Local interleukin-2 therapy for cancer and its effector induction mechanisms. Oncology 1994;51:170-6.
32. Asher AL, Mule JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factors against tumors. J Immunol 1991;146:3227-34.
33. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
34. Russell SJ, Eccles SA, Flemming CL, Johnson CA, Collins MK. Decreased tumorigenicity of transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 1991;47:244-51.
35. Walther W, Fichtner I, Uckert W. Retrovirus-mediated gene transfer of tumor necrosis factor alpha into colon carcinoma cells generates a growth inhibition. Anticancer Res 1993;13:1565-74.
36. Rosenberg S. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. Hum Gene Ther 1992;3:57-73.
37. Rosenberg S. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Hum Gene Ther 1992;3:75-90.
38. Morgavi P, Cimoli G, Ottoboni C, Michelotti A, Conte P, Parodi S, et al. Sensitization of human glioblastoma T98G cells to VP16 and VM26 by human tumor necrosis factor. Anticancer Res 1995;15:1423-8.
39. Ishihara H, Kajiwara K, Ohshita N, Kimura Y, Nishizaki T, Ito H. IFN-beta inhibition of etoposide resistance acquisition in vitro: studies using a human glioblastoma cell line. Anticancer Res 1995;15:283-7.
40. Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. Blood 1989;74:1723-7.
41. Scala S, Pacelli R, Iaffaioli RV, Normanno N, Pepe S, Frasci G, et al. Reversal of Adriamycin resistance by recombinant alpha-interferon in multidrug resistant human colon carcinoma LoVo-doxorubicin cells. Cancer Res 1991;51:4898-902.
42. Kang Y, Perry RR. Effect of alpha-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Res 1994;54:2952-8.